Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer

K Yamaguchi, T Shimamura, I Hyodo, W Koizumi, T Doi, H Narahara, Y Komatsu, T Kato, S Saitoh, T Akiya, M Munakata, Y Miyata, Y Maeda, H Takiuchi, S Nakano, T Esaki, F Kinjo, Y Sakata, K Yamaguchi, T Shimamura, I Hyodo, W Koizumi, T Doi, H Narahara, Y Komatsu, T Kato, S Saitoh, T Akiya, M Munakata, Y Miyata, Y Maeda, H Takiuchi, S Nakano, T Esaki, F Kinjo, Y Sakata

Abstract

The aims of this phase I/II study of docetaxel and S-1 were to determine the dose-limiting toxicity (DLT), maximum-tolerated dose (MTD), and recommended dose (RD) in the phase I part and to explore the tumour response, survival and safety in the phase II part. Patients with histologically- or cytologically confirmed unresectable or recurrent gastric cancer were eligible. Treatment consisted of intravenous docetaxel on day 1 (starting dose 50 mg m(-2)) and oral S-1 at a fixed dose of 40 mg m(-2) twice daily on days 1-14, every 4 weeks up to six cycles. Nine patients took part in the phase I portion of the study. The MTD of docetaxel was determined to be 50 mg m(-2), with the DLTs of grade 3 infection associated with grade 3 neutropenia and grade 4 neutropenia during S-1 administration. The RD of docetaxel was 40 mg m(-2) in combination with S-1 40 mg m(-2) b.i.d. The efficacy and safety of this regimen was therefore assessed in 46 patients with at least one measurable lesion. The overall response rate and estimated median overall survival were 46% (95% CI, 31-61%) and 14.0 months (8.3-17.3 months), respectively. The most common grade 3/4 toxicity was neutropenia (67% of patients), which was predictable and manageable. This regimen showed promising activity with moderate toxicities in advanced gastric cancer.

Figures

Figure 1
Figure 1
The cumulative probability of survivals. The solid and dotted lines present overall and progression-free survivals estimated by the Kaplan–Meier method in 46 patients, respectively.

References

    1. Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Filho SC, Majlis A, Assadourian S, Van Cutsem E (2005) Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 23: 5660–5667
    1. Alberts SR, Cervantes A, van de Velde CJH (2003) Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 14(Suppl 2): ii31–ii36
    1. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F (1995) Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs 6: 339–368
    1. Chollet P, Schoffski P, Weigang-Kohler K, Schellens JH, Cure H, Pavlidis N, Grunwald V, De Boer R, Wanders J, Fumoleau P, EORTC Early Clinical Studies Group (2003) Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 39: 1264–1270
    1. Constenla M, Garcia-Arroyo R, Lorenzo I, Carrete N, Campos B, Palacios P (2002) Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study. Gastric Cancer 5: 142–147
    1. Denis JN, Correa A, Greene AE (1990) An improved synthesis of the Taxol side chain and of RP56976. J Org Chem 55: 1957–1959
    1. De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, Infusino S, Damiano V, Simeone E, Diadema MR, Lieto E, Castellano P, Pepe S, De Placido S, Galizia G, Di Martino N, Ciardiello F, Catalano G, Bianco AR (2005) A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 92: 1644–1649
    1. Einzig AI, Neuberg D, Remick SC, Karp DD, O'Dwyer PJ, Stewart JA, Benson III AB (1996) Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 13: 87–93
    1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55: 10–30
    1. Kim H, Kim YH, Shim BY, Shin SW, Moon H (2006) Phase I study for the escalation of docetaxel with fixed dose of TS1 in advanced gastric cancer. ASCO American Society of Clinical Oncology Gastrointestinal Cancers Symposium: Abstract No 87
    1. Koizumi W, Kurihara M, Nakano S, Hasegawa K, for the S-1 Cooperative Gastric Cancer Study Group (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 58: 191–197
    1. Mai M, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J, Hirabayashi N, Taguchi T, Furue H (1999) A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (Group B). Jpn J Cancer Chemother 26: 487–496 (in Japanese with English abstract)
    1. Moiseyenko VM, Ajani JA, Tjulandin SA, Majlis A, Constenla M, Boni C, Anelli A, Yver AJ, Van Cutsem E, on behalf of the TAX 325 Study Group (2005) Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). Proc Am Soc Clin Oncol 23: 308s (abstract 4002)
    1. Ohtsu A (2005) Current status and future prospects of chemotherapy for metastatic gastric cancer: a review. Gastric Cancer 8: 95–102
    1. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S (2003) Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21: 54–59
    1. Park SR, Chun JH, Yu MS, Kim YW, Lee JH, Choi IJ, Kim CG, Lee JS, Bae JM, Kim HKA (2006) Phase I study of S1 and weekly docetaxel in metastatic gastric cancer. ASCO American Society of Clinical Oncology Gastrointestinal Cancers Symposium: Abstract No 82
    1. Park YH, Ryoo B-Y, Choi S-J, Kim H-T (2004) A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 90: 1329–1333
    1. Rino Y, Takanashi Y, Yukawa N, Saeki H, Wada H, Kanari M, Yamada R, Satoh T, Yamamoto N, Imada TA (2006) Phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer. Anticancer Res 26: 1455–1462
    1. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger H, Cavalli F, Alberto P, Castiglione M, Goldhirsch A (2000) Docetaxel (Taxotere®)-cisplatin (TC): an effective drug combination in gastric carcinoma. Ann Oncol 11: 301–306
    1. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715–1720
    1. Satoh KT, Okamoto I, Miyazaki M, Shimizu T, Ozaki T, Nakagawa K, Fukuoka M (2006) S-1 plus docetaxel in patients with advanced gastric cancer: a phase I study. ASCO American Society of Clinical Oncology Gastrointestinal Cancers Symposium: Abstract No 84T
    1. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anti-cancer Drugs 7: 548–557
    1. Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, Wanders J, Franklin H, LeBail N, Verweij J (1994) Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 70: 380–383
    1. Takahashi I, Emi Y, Kakeji Y, Tokunaga E, Ushiro S, Oki E, Watanabe M, Baba H, Maehara Y (2006) Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer. Oncol Rep 15: 849–854
    1. Taguchi T, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J, Hirabayashi N (1998) Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (Group A). Jpn J Cancer Chemothr 25: 1915–1924 (in Japanese with English abstract)
    1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205–216
    1. Thuss-Patience P, Kretzschmar A, Repp M, Kingreen D, Hemnesser D, Micheel S, Pink D, Dörken B, Reichardt P (2005) Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol 23: 494–501
    1. Van Custem E, Moiseyenko V, Tjulandin S, Fodor M, Boni C, Zuber E, Assadourian S (2003) Docetaxel (D), cisplatin (C), 5-fluorouracil (F) compared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naïve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): interim results of a randomised phase III trial (V325). Eur J Cancer, (Suppl 1): s20 (abstract 51A)
    1. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Dos Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA (2000) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18: 2648–2657
    1. Wada Y, Yoshida K, Suzuki T, Mizuiri H, Konishi K, Ukon K, Tanabe K, Sakata Y, Fukushima M (2006) Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer Mar 23 [E-pub ahead of print]
    1. Wöhrer SS, Raderer M, Hejna M (2004) Palliative chemotherapy for advanced gastric cancer. Ann Oncol 15: 1585–1595
    1. Yoshida K, Hirabayashi N, Takiyama W, Ninomiya M, Takakura N, Sakamoto J, Nishiyama M, Toge T (2004) Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. Anticancer Res 24: 1843–1851

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit